Gene shot into heart shows promise in early safety trial
NCT ID NCT01422772
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a gene therapy called VM202RY in 9 people with ischemic heart disease who had incomplete revascularization after bypass surgery. The therapy was injected directly into heart muscle areas that still had poor blood flow. The main goal was to check safety over 6 months, and researchers also looked at changes in heart function using MRI.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
VM202RY (Engensis) gene therapy
What this could lead to
If successful, this could lead to a new gene-based treatment to improve blood flow and heart function in people with severe heart disease who cannot be fully treated with bypass surgery alone.
What could go wrong
This is a very early, small trial with only 9 participants, so results may not apply to everyone. The main goal is safety, not effectiveness, and gene therapies can have unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ISCHEMIC HEART DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Seoul National University Hospital
Seoul, South Korea